EV
EVKIF.US Evonik Industries AG
- Market cap
- USD 10.4B
- P/E
- 52.0x
- P/B
- 1.16x
- ROE
- 2.6%
- Dividend yield
- 5.16%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EVKIF.US undervalued?
Graham numberEVKIF.US trades 63.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evonik Industries AG fundamental analysis
No fundamental analysis for Evonik Industries AG yet.
Evonik Industries AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silane…
Full company profileEvonik Industries AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evonik Industries AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 12.7B | 14.4B | 15.0B | 13.1B | 12.2B | 15.0B | 18.5B | 15.3B | 15.2B | 14.1B | 14.8B |
| Gross Profit | 4.20B | 4.48B | 4.63B | 3.70B | 3.37B | 4.03B | 4.23B | 2.70B | 3.74B | 3.24B | 3.56B |
| Operating Income | 1.46B | 1.41B | 1.67B | 1.29B | 886M | 1.24B | 1.43B | -30.0M | 639M | 641M | 1.47B |
| EBITDA | 2.10B | 2.28B | 1.88B | 2.16B | 1.87B | 2.29B | 2.17B | 1.73B | 1.76B | 1.84B | 2.70B |
| Net Income | 844M | 717M | 932M | 2.11B | 465M | 746M | 540M | -465M | 222M | 265M | 210M |
| EPS | 1.81 | 1.54 | 2.00 | 4.52 | 1.00 | 1.60 | 1.16 | -1.00 | 0.48 | 0.57 | 0.45 |
| Balance Sheet | |||||||||||
| Total Assets | 19.6B | 19.9B | 20.3B | 22.0B | 20.9B | 22.3B | 21.8B | 19.9B | 19.8B | 18.0B | 19.1B |
| Total Liabilities | 11.9B | 12.4B | 12.5B | 13.0B | 12.8B | 12.9B | 10.8B | 11.0B | 10.7B | 9.81B | 10.9B |
| Shareholders' Equity | 7.66B | 7.44B | 7.73B | 8.97B | 8.01B | 9.29B | 11.0B | 8.91B | 9.02B | 8.11B | 8.14B |
| Cash & Short-term Investments | 4.67B | 1.05B | 1.13B | 2.38B | 1.06B | 919M | 1.12B | 1.03B | 618M | 623M | 541M |
| Total Debt | 3.52B | 3.99B | 3.86B | 4.46B | 3.84B | 3.64B | 4.23B | 4.26B | 3.78B | 3.87B | 4.41B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.76B | 1.55B | 1.70B | 1.32B | 1.73B | 1.82B | 1.65B | 1.59B | 1.71B | 1.44B | 1.46B |
| Capital Expenditure | 948M | 1.04B | 1.03B | 880M | 956M | 886M | 865M | 793M | 840M | 748M | 791M |
| Free Cash Flow | 810M | 511M | 672M | 441M | 771M | 929M | 785M | 801M | 873M | 695M | 669M |
| Ratios | |||||||||||
| ROE | 11.0% | 9.6% | 12.1% | 23.5% | 5.8% | 8.0% | 4.9% | -5.2% | 2.5% | 3.3% | 2.6% |
| ROA | 4.3% | 3.6% | 4.6% | 9.6% | 2.2% | 3.3% | 2.5% | -2.3% | 1.1% | 1.5% | 1.1% |
| Net Profit Margin | 6.6% | 5.0% | 6.2% | 16.1% | 3.8% | 5.0% | 2.9% | -3.0% | 1.5% | 1.9% | 1.4% |
| Debt to Equity | 0.46x | 0.54x | 0.50x | 0.50x | 0.48x | 0.39x | 0.39x | 0.48x | 0.42x | 0.48x | 0.54x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evonik Industries AG dividends
- Dividend yield
- 5.16%
- Forward dividend
- 1.15 USD
- Payout ratio
- 205.7%
- Ex-dividend date
- Jun 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 545M | 1.17 | 205.7% |
| 2024 | EUR 545M | 1.17 | 245.5% |
| 2023 | EUR 545M | 1.17 | - |
| 2022 | EUR 545M | 1.17 | 100.9% |
| 2021 | USD 536M | 1.15 | 71.8% |
| 2020 | USD 536M | 1.15 | 115.3% |
| 2019 | USD 536M | 1.15 | 25.5% |
| 2018 | USD 536M | 1.15 | 57.5% |
| 2017 | USD 536M | 1.15 | 74.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Evonik Industries AG
- Insiders 46.52%
- Institutions 40.11%
- Public & others 13.37%
- Shares outstanding 466M
- Free float 260M
Evonik Industries AG company profile
- Company name
- Evonik Industries AG
- Ticker
- EVKIF.US
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 30,319
- Fiscal year end
- December
- Address
- Rellinghauser Strasse 1-11, Essen, Germany, 45128
- Phone
- 49 201 177 3315
- Website
- evonik.com
About Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and D-/L-methionine and lysine for animal nutrition. Its Custom Solutions segment provides additives for coatings, adhesives, sealants, polyurethane foams, and lubricants for the cosmetic, cleaning, and pharmaceutical industries. The Infrastructure segment engages in the infrastructure activities and offers butadiene, MTBE, butene-1, isononanol, and DINP for use in the plastic and packaging industries, production of rubber and fuels, and as plasticizers in the construction and automotive sectors. The company was founded in 1847 and is headquartered in Essen, Germany.
Evonik Industries AG management
10- Mr. Thomas WesselChief Human Resources Officer, Labor Relations Director & Member of Executive Board · born 1963
- Ms. Lauren KjeldsenCOO of Custom Solutions & Member of the Management Board
- Dr. Claudine MollenkopfCOO of Advanced Technologies & Member of the Management Board · born 1966
- Dr. Claus RettigInterim CEO & Deputy Chairman of the Management Board
- Mr. Michael Rauch L.L.M., M.B.A.CFO & Member of Executive Board · born 1972
- Dr. Wilfried OstendorfHead of Production and Technology
- Mr. Christoph FinkeSenior Vice President of Investor Relations
- Mr. Thomas MahlstedtVice President M&A, Corporate Legal & Compliance
- Mr. Christian SchmidHead of Corporate Communications · born 1971
- Dr. Stefan MackHead of the Methionine & Derivatives Product Line